Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. 

Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.

Biotechnology

Vevo

Nima Alidoust

Hani Goodarzi

Daniele Merico

Airol Ubas

Yasmin Sameni

Johnny Yu

The Leadership Team at Vevo Therapeutics is responsible for guiding the company's strategic vision and overseeing its innovative approaches to drug discovery using advanced AI models and in vivo data generation. Comprised of experienced industry leaders and experts in computational biology, genomics, and chemistry, the team collaborates to enhance the Mosaic platform and drive research towards developing effective therapies for patients. Their collective expertise ensures that Vevo remains at the forefront of biotechnology, successfully navigating challenges in targeting previously undruggable diseases.

Leadership Team

Research and Development

Leadership Team

About

Team members

Other teams at Vevo

Research and Development